Leadership & Pay ·
At its 2026 Annual Meeting, Ocular Therapeutix, Inc. stockholders approved an amendment to its 2021 Stock Incentive…
OCULOcular Therapeutix, Inc
At its 2026 Annual Meeting, Ocular Therapeutix, Inc. stockholders approved an amendment to its 2021 Stock Incentive Plan to increase the number of shares issuable under the plan by 10,000,000 shares. The Board appointed Jason Robins as Chief Financial Officer, whose annual base salary will increase to $535,100 effective July 1, 2026, with a 45% target cash bonus. Ocular Therapeutix, Inc. is a biopharmaceutical company that develops and commercializes ophthalmic therapeutic products.